About This Page
This is a clinician-written, evidence-based summary aligned to the USMLE Step 2 CK Content Outline. It is intended for medical students preparing for USMLE Step 2 CK. Management reflects current ACC/AHA, USPSTF, and APA guidelines. Always cross-reference with UpToDate, institutional protocols, and clinical judgment.
The Bottom Line
- Clinically significant hypoglycemia in diabetes is glucose <54 mg/dL; severe hypoglycemia requires assistance regardless of measured value
- Whipple triad: symptoms + low plasma glucose + symptom relief after glucose correction
- Autonomic symptoms: sweating, tremor, palpitations, anxiety, hunger; neuroglycopenic symptoms: confusion, seizure, coma
- Conscious patient: oral fast-acting carbohydrate using the 15-15 rule
- Unconscious or unable to swallow: glucagon or IV dextrose immediately
Overview
Hypoglycemia is a common and potentially dangerous complication of diabetes treatment and a high-yield emergency on Step 2 CK. It is most often caused by insulin, sulfonylureas, missed meals, exercise, alcohol, renal impairment, or medication dosing errors. Non-diabetic hypoglycemia is less common and requires confirmation with Whipple triad before extensive workup. Recurrent episodes can cause hypoglycemia unawareness due to impaired autonomic warning responses.
Epidemiology
Hypoglycemia is especially common in type 1 diabetes and in insulin-treated type 2 diabetes. Severe events are more likely in older adults, chronic kidney disease, long diabetes duration, tight glycemic targets, cognitive impairment, food insecurity, and prior severe hypoglycemia. Sulfonylurea-associated hypoglycemia is particularly prolonged in older adults and patients with kidney disease. Alcohol contributes by inhibiting hepatic gluconeogenesis, especially after fasting.
Clinical Features
Symptoms
Sweating, tremor, palpitations, anxiety, and hunger from adrenergic activation
Paresthesias and warmth from cholinergic activation
Confusion, behavioral change, visual disturbance, slurred speech, or weakness from neuroglycopenia
Seizure, loss of consciousness, or coma in severe hypoglycemia
No warning symptoms in hypoglycemia unawareness
Signs
Diaphoresis, tachycardia, tremor
Altered mental status that can mimic intoxication, stroke, or seizure disorder
Focal neurologic deficits may occur and resolve with glucose correction
Hypothermia in severe or prolonged hypoglycemia
Normal exam after treatment does not exclude a dangerous medication cause
Investigations
First-line
Point-of-care glucoseImmediate bedside test in any patient with altered mental status, seizure, syncope, or diabetes symptoms
Plasma glucoseConfirm low glucose if diagnosis uncertain, especially in non-diabetic patients
Medication reviewInsulin, sulfonylureas, meglitinides, alcohol, quinolones, beta-blockers, and renal dosing errors
Second-line
Critical sample during spontaneous hypoglycemiaIf non-diabetic or unexplained: plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, sulfonylurea screen, cortisol if adrenal insufficiency suspected
Renal and liver function testsRenal failure prolongs insulin/sulfonylurea effect; liver failure impairs glycogenolysis/gluconeogenesis
HbA1cAssesses overtreatment or mismatch between glycemic targets and risk
Specialist
72-hour supervised fastGold standard for suspected insulinoma when spontaneous critical sample is not captured
Imaging for insulinomaPancreatic CT/MRI or endoscopic ultrasound after biochemical confirmation
1
Immediate treatment — conscious and able to swallow
- Give 15-20 g fast-acting carbohydrate: glucose tablets, juice, regular soda, or gel
- Recheck glucose in 15 minutes; repeat if still low
- Once corrected, give longer-acting carbohydrate or meal if next meal is not imminent
2
Severe hypoglycemia or unable to swallow
- Give glucagon by nasal, autoinjector, or IM/SQ route if IV access unavailable
- If IV access available: dextrose IV bolus followed by infusion if recurrent
- Do not give oral intake to a drowsy or unconscious patient because of aspiration risk
3
Sulfonylurea-induced hypoglycemia
- Observe for recurrence; hypoglycemia may be prolonged
- Give octreotide to suppress insulin secretion after sulfonylurea overdose or recurrent episodes
- Admit high-risk patients, older adults, renal impairment, and intentional overdose
4
Prevention
- Adjust insulin/sulfonylurea dose, meal plan, exercise timing, and alcohol use
- Prescribe glucagon to anyone at risk of severe hypoglycemia
- Use CGM and less stringent A1c targets in patients with recurrent severe hypoglycemia or hypoglycemia unawareness
Complications
- Seizures and coma: Neuroglycopenia can rapidly become life-threatening
- Falls and trauma: Particularly in older adults
- Cardiac arrhythmias: Catecholamine surge and QT prolongation can precipitate sudden death
- Hypoglycemia unawareness: Recurrent episodes blunt autonomic warning symptoms
- Overcorrection hyperglycemia: Excess carbohydrate can worsen glycemic variability
USMLE Step 2 CK Exam Tips
- 1Always check glucose in altered mental status — it is fast, reversible, and commonly tested
- 2Whipple triad is required before extensive workup for non-diabetic hypoglycemia
- 3High insulin + high C-peptide = endogenous insulin or sulfonylurea; high insulin + low C-peptide = exogenous insulin
- 4Sulfonylurea hypoglycemia recurs after dextrose; octreotide is the key treatment
- 5Alcoholic patient who has not eaten: hypoglycemia from impaired gluconeogenesis
- 6Beta-blockers can mask adrenergic symptoms but sweating often persists
- 7Glucagon works poorly when glycogen stores are depleted, such as prolonged fasting or liver failure
practicetest your knowledge on hypoglycemiaApply what you've learnt with USMLE Step 2 CK-style questions from the iatroX Q-Bank — endocrine and beyond.
open q-bank